There are 2789 resources available
Discussion 960MO, 961MO and 962MO
Presenter: Thomas Gajewski
Session: Mini oral session - Investigational immunotherapy
Resources:
Slides
Webcast
960MO - Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC
Presenter: Daniel Catenacci
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
961MO - Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers
Presenter: Marshall Posner
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
962MO - A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Presenter: Julia Katharina Schwarze
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
963MO - Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201
Presenter: Jaume Mora
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
964MO - Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844)
Presenter: Evanthia Roussos Torres
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
860MO - Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC)
Presenter: Hye Ryun Kim
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
861MO - Spatial distribution of CD8+ and FoxP3+ in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (HNSCC)
Presenter: Joseph Curry
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
LBA52 - Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study
Presenter: Lin Shen
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA53 - Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
Presenter: Jianming Xu
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast